Future longitudinal studies should aim to address whether this peripheral biomarker correlates with the deposition of amyloid and tau in the AD brain and confirm if unfolded p53 is able to diagnose AD at its early stages, predicting if patients with MCI are predisposed to develop AD. This evidence concerns the gene MAPT and Alzheimer disease.